Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 AltheRx Gets Patent for OAB Combo | Contract Pharma

What are you searching for?

Sign in
Trials & Filings

AltheRx Gets Patent for OAB Combo

Covers solabegron in conjunction with available antimuscarinics

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

AltheRx Pharmaceuticals has received a Notice of Allowance from the United States Patent and Trademark Office for the company’s U.S. Patent Application claiming a method of use for solabegron in combination with all commercially available antimuscarinics at both therapeutic and sub-therapeutic doses for the treatment of overactive bladder (OAB).

AltheRx is currently developing solabegron, a novel beta 3-adrenergic receptor agonist with high affinity and selectivity, for the treatment of OAB. Phase II results demonstrated a statistically significant improvement with solabegron as compared to placebo, with favorable tolerability. Solabegron is poised to enter Phase III clinical studies in the EU and the U.S.; AltheRx is in active business development discussions to progress the drug through late stage clinical development and eventually into global commercialization.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics